Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension trial of NN1250 versus insulin glargine with insulin aspart in type 2 diabetes
2009-015816-17Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2010
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in type 2 diabetes mellitus (T2DM) comparing NN1250 + insulin aspart ± metformin ± pioglitazone with Insulin glargine + insulin aspart ± metformin ± pioglitazone (2 arms). Primary endpoint: Treatment-emergent adverse events. Started Feb 2010; status: completed.
02
Drugs
insulin degludecinsulin glargineinsulin aspartmetforminpioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2009-015816-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015816-17.